We have located links that may give you full text access.
HIV care retention in three multi-month ART dispensing: a retrospective cohort study in mozambique.
AIDS 2024 April 24
OBJECTIVE: Evaluate the effect of three multi-month dispensing (3MMD) of antiretroviral therapy (ART) on HIV care retention in southern Mozambique.
DESIGN: Retrospective cohort study.
METHODS: We analysed routine health data from people living with HIV (PLHIV) ≥10 years old who started ART between January 2018 and March 2021. Individuals were followed until December 2021. Cox proportional-hazards models were used to compare attrition (lost to follow-up, death, and transfer out) between 3MMD and monthly ART dispensing. Results were stratified by time on ART before 3MMD enrolment: "early enrollers" (<6 months on ART) and "established enrollers" (≥6 months on ART), and age groups: adolescents and youth (AYLHIV) (10-24 years) and adults (≥25 years).
RESULTS: We included 7,378 PLHIV (25% AYLHIV, 75% adults), with 59% and 62% enrolled in 3MMD, respectively. Median follow-up time was 11.3 (IQR: 5.7-21.6) months for AYLHIV and 10.2 (IQR: 4.8-20.9) for adults. Attrition was lower in PLHIV enrolled in 3MMD compared to monthly ART dispensing, in both established (aHR AYLHIV = 0.65; 95%CI: 0.54-0.78 and aHR adults = 0.50; 95%CI: 0.44-0.56) and early enrollers (aHR AYLHIV = 0.70; 95%CI: 0.58-0.85 and aHR adults = 0.63; 95%CI: 0.57-0.70). Among individuals in 3MMD, male gender (aHR = 1.30; 95%CI: 1.18-1.44) and receiving care in a medium/low-volume healthcare facility (aHR = 1.18; 95%CI: 1.03-1.34) increased attrition risk. Conversely, longer ART time before 3MMD enrolment (aHR = 0.93; 95% CI: 0.92-0.94 per one-month increase) and age ≥45 years (aHR = 0.77, 95%CI: 0.67-0.89) reduced risk of attrition.
CONCLUSIONS: 3MMD improves retention in care compared to monthly dispensing among established and early enrollers, although to a lesser extent among the latter.
DESIGN: Retrospective cohort study.
METHODS: We analysed routine health data from people living with HIV (PLHIV) ≥10 years old who started ART between January 2018 and March 2021. Individuals were followed until December 2021. Cox proportional-hazards models were used to compare attrition (lost to follow-up, death, and transfer out) between 3MMD and monthly ART dispensing. Results were stratified by time on ART before 3MMD enrolment: "early enrollers" (<6 months on ART) and "established enrollers" (≥6 months on ART), and age groups: adolescents and youth (AYLHIV) (10-24 years) and adults (≥25 years).
RESULTS: We included 7,378 PLHIV (25% AYLHIV, 75% adults), with 59% and 62% enrolled in 3MMD, respectively. Median follow-up time was 11.3 (IQR: 5.7-21.6) months for AYLHIV and 10.2 (IQR: 4.8-20.9) for adults. Attrition was lower in PLHIV enrolled in 3MMD compared to monthly ART dispensing, in both established (aHR AYLHIV = 0.65; 95%CI: 0.54-0.78 and aHR adults = 0.50; 95%CI: 0.44-0.56) and early enrollers (aHR AYLHIV = 0.70; 95%CI: 0.58-0.85 and aHR adults = 0.63; 95%CI: 0.57-0.70). Among individuals in 3MMD, male gender (aHR = 1.30; 95%CI: 1.18-1.44) and receiving care in a medium/low-volume healthcare facility (aHR = 1.18; 95%CI: 1.03-1.34) increased attrition risk. Conversely, longer ART time before 3MMD enrolment (aHR = 0.93; 95% CI: 0.92-0.94 per one-month increase) and age ≥45 years (aHR = 0.77, 95%CI: 0.67-0.89) reduced risk of attrition.
CONCLUSIONS: 3MMD improves retention in care compared to monthly dispensing among established and early enrollers, although to a lesser extent among the latter.
Full text links
Related Resources
Trending Papers
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app